Mutations of human cytochrome P450 reductase differentially modulate heme oxygenase-1 activity and oligomerization

Christopher C Marohnic1, Warren J Huber Iii, J Patrick Connick

  • 1The University of Texas Health Science Center at San Antonio, Department of Biochemistry, USA. masters@uthscsa.edu

Insights

Genetic variations in NADPH-cytochrome P450 oxidoreductase (CYPOR) diminish heme degradation by heme oxygenase-1 (HO-1). Different CYPOR variants show varying impacts on HO-1 activity, potentially complicating CYPOR deficiency.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Genetics

Background:

  • Genetic variations in POR, encoding NADPH-cytochrome P450 oxidoreductase (CYPOR), affect numerous cytochrome P450 functions.
  • These variations can also impede the degradation of heme by heme oxygenase-1 (HO-1).

Purpose of the Study:

  • To investigate the impact of naturally occurring human CYPOR variants on heme degradation by HO-1.
  • To characterize the interaction between CYPOR variants and HO-1, including binding affinities and optimal ratios.

Main Methods:

  • Purified human CYPOR variants, HO-1, and biliverdin reductase were reconstituted in lipid vesicles.
  • Assays measured NADPH-dependent conversion of heme to bilirubin for wild-type (WT) and variant CYPOR.
  • The effect of FMN, FAD, and varying CYPOR:HO-1 ratios on activity was examined.

Main Results:

  • All tested CYPOR variants showed reduced bilirubin production compared to WT, indicating diminished HO-1 activity.
  • Apparent affinity of the CYPOR-HO-1 complex was lower for variants than WT.
  • FMN or FAD partially restored activity for specific variants (Y181D, Y459H, V492E).
  • Only the Y181D variant inhibited HO-1 activity by sequestering it, suggesting differential binding affinities among variants.
  • Optimal CYPOR:HO-1 ratio for activity was 1:2, supporting HO-1 oligomerization.

Conclusions:

  • Human POR mutations lead to varying degrees of diminished HO-1 activity.
  • These findings suggest that CYPOR variants have differential binding affinities with redox partners.
  • The impact on HO-1 activity may further complicate the clinical presentation of CYPOR deficiency.

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...